Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes

Mark C. Genovese, Joan M. Bathon, Richard W. Martin, Roy M. Fleischmann, John R. Tesser, Michael H. Schiff, Edward C. Keystone, Mary Chester Wasko, Larry W. Moreland, Arthur L. Weaver, Joseph Markenson, Grant W. Cannon, George Spencer-Green, Barbara K. Finck

Research output: Contribution to journalArticle

Abstract

Objective. To compare the clinical and radio-graphic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 years and to assess the safety of this therapy. Methods. In the Enbrel ERA (early rheumatoid arthritis) trial, 632 patients with early, active RA were randomized to receive either twice-weekly subcutaneous etanercept (10 mg or 25 mg) or weekly oral MTX (mean dosage 19 mg per week) for at least 1 year in a double-blind manner. Following the blinded phase of the trial, 512 patients continued to receive the therapy to which they had been randomized for up to 1 additional year, in an open-label manner. Radiograph readers remained blinded to treatment group assignment and the chronologic order of images. Results. At 24 months, more 25-mg etanercept patients than MTX patients met American College of Rheumatology 20% improvement criteria (72% and 59%, respectively; P = 0.005), and more had no increase in total score and erosion scores on the Sharp scale (P = 0.017 and P = 0.012, respectively). The mean changes in total Sharp score and erosion score in the 25-mg etanercept group (1.3 and 0.66 units, respectively) were significantly lower than those in the MTX group (3.2 and 1.86 units, respectively; P = 0.001). Significantly more patients in the 25-mg etanercept group (55%) than in the MTX group (37%) had at least 0.5 units of improvement in the Health Assessment Questionnaire disability index (P <0.001). Fewer patients in the etanercept group than in the MTX group experienced adverse events or discontinued treatment because of adverse events. Conclusion. Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.

Original languageEnglish (US)
Pages (from-to)1443-1450
Number of pages8
JournalArthritis and Rheumatism
Volume46
Issue number6
DOIs
StatePublished - 2002

Fingerprint

Methotrexate
Rheumatoid Arthritis
Etanercept
Therapeutics
Radio
Safety
Health

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Genovese, M. C., Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., ... Finck, B. K. (2002). Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis and Rheumatism, 46(6), 1443-1450. https://doi.org/10.1002/art.10308

Etanercept versus methotrexate in patients with early rheumatoid arthritis : Two-year radiographic and clinical outcomes. / Genovese, Mark C.; Bathon, Joan M.; Martin, Richard W.; Fleischmann, Roy M.; Tesser, John R.; Schiff, Michael H.; Keystone, Edward C.; Wasko, Mary Chester; Moreland, Larry W.; Weaver, Arthur L.; Markenson, Joseph; Cannon, Grant W.; Spencer-Green, George; Finck, Barbara K.

In: Arthritis and Rheumatism, Vol. 46, No. 6, 2002, p. 1443-1450.

Research output: Contribution to journalArticle

Genovese, MC, Bathon, JM, Martin, RW, Fleischmann, RM, Tesser, JR, Schiff, MH, Keystone, EC, Wasko, MC, Moreland, LW, Weaver, AL, Markenson, J, Cannon, GW, Spencer-Green, G & Finck, BK 2002, 'Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes', Arthritis and Rheumatism, vol. 46, no. 6, pp. 1443-1450. https://doi.org/10.1002/art.10308
Genovese, Mark C. ; Bathon, Joan M. ; Martin, Richard W. ; Fleischmann, Roy M. ; Tesser, John R. ; Schiff, Michael H. ; Keystone, Edward C. ; Wasko, Mary Chester ; Moreland, Larry W. ; Weaver, Arthur L. ; Markenson, Joseph ; Cannon, Grant W. ; Spencer-Green, George ; Finck, Barbara K. / Etanercept versus methotrexate in patients with early rheumatoid arthritis : Two-year radiographic and clinical outcomes. In: Arthritis and Rheumatism. 2002 ; Vol. 46, No. 6. pp. 1443-1450.
@article{b95a6395404c4ddea48334ad26962b02,
title = "Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes",
abstract = "Objective. To compare the clinical and radio-graphic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 years and to assess the safety of this therapy. Methods. In the Enbrel ERA (early rheumatoid arthritis) trial, 632 patients with early, active RA were randomized to receive either twice-weekly subcutaneous etanercept (10 mg or 25 mg) or weekly oral MTX (mean dosage 19 mg per week) for at least 1 year in a double-blind manner. Following the blinded phase of the trial, 512 patients continued to receive the therapy to which they had been randomized for up to 1 additional year, in an open-label manner. Radiograph readers remained blinded to treatment group assignment and the chronologic order of images. Results. At 24 months, more 25-mg etanercept patients than MTX patients met American College of Rheumatology 20{\%} improvement criteria (72{\%} and 59{\%}, respectively; P = 0.005), and more had no increase in total score and erosion scores on the Sharp scale (P = 0.017 and P = 0.012, respectively). The mean changes in total Sharp score and erosion score in the 25-mg etanercept group (1.3 and 0.66 units, respectively) were significantly lower than those in the MTX group (3.2 and 1.86 units, respectively; P = 0.001). Significantly more patients in the 25-mg etanercept group (55{\%}) than in the MTX group (37{\%}) had at least 0.5 units of improvement in the Health Assessment Questionnaire disability index (P <0.001). Fewer patients in the etanercept group than in the MTX group experienced adverse events or discontinued treatment because of adverse events. Conclusion. Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.",
author = "Genovese, {Mark C.} and Bathon, {Joan M.} and Martin, {Richard W.} and Fleischmann, {Roy M.} and Tesser, {John R.} and Schiff, {Michael H.} and Keystone, {Edward C.} and Wasko, {Mary Chester} and Moreland, {Larry W.} and Weaver, {Arthur L.} and Joseph Markenson and Cannon, {Grant W.} and George Spencer-Green and Finck, {Barbara K.}",
year = "2002",
doi = "10.1002/art.10308",
language = "English (US)",
volume = "46",
pages = "1443--1450",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Etanercept versus methotrexate in patients with early rheumatoid arthritis

T2 - Two-year radiographic and clinical outcomes

AU - Genovese, Mark C.

AU - Bathon, Joan M.

AU - Martin, Richard W.

AU - Fleischmann, Roy M.

AU - Tesser, John R.

AU - Schiff, Michael H.

AU - Keystone, Edward C.

AU - Wasko, Mary Chester

AU - Moreland, Larry W.

AU - Weaver, Arthur L.

AU - Markenson, Joseph

AU - Cannon, Grant W.

AU - Spencer-Green, George

AU - Finck, Barbara K.

PY - 2002

Y1 - 2002

N2 - Objective. To compare the clinical and radio-graphic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 years and to assess the safety of this therapy. Methods. In the Enbrel ERA (early rheumatoid arthritis) trial, 632 patients with early, active RA were randomized to receive either twice-weekly subcutaneous etanercept (10 mg or 25 mg) or weekly oral MTX (mean dosage 19 mg per week) for at least 1 year in a double-blind manner. Following the blinded phase of the trial, 512 patients continued to receive the therapy to which they had been randomized for up to 1 additional year, in an open-label manner. Radiograph readers remained blinded to treatment group assignment and the chronologic order of images. Results. At 24 months, more 25-mg etanercept patients than MTX patients met American College of Rheumatology 20% improvement criteria (72% and 59%, respectively; P = 0.005), and more had no increase in total score and erosion scores on the Sharp scale (P = 0.017 and P = 0.012, respectively). The mean changes in total Sharp score and erosion score in the 25-mg etanercept group (1.3 and 0.66 units, respectively) were significantly lower than those in the MTX group (3.2 and 1.86 units, respectively; P = 0.001). Significantly more patients in the 25-mg etanercept group (55%) than in the MTX group (37%) had at least 0.5 units of improvement in the Health Assessment Questionnaire disability index (P <0.001). Fewer patients in the etanercept group than in the MTX group experienced adverse events or discontinued treatment because of adverse events. Conclusion. Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.

AB - Objective. To compare the clinical and radio-graphic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 years and to assess the safety of this therapy. Methods. In the Enbrel ERA (early rheumatoid arthritis) trial, 632 patients with early, active RA were randomized to receive either twice-weekly subcutaneous etanercept (10 mg or 25 mg) or weekly oral MTX (mean dosage 19 mg per week) for at least 1 year in a double-blind manner. Following the blinded phase of the trial, 512 patients continued to receive the therapy to which they had been randomized for up to 1 additional year, in an open-label manner. Radiograph readers remained blinded to treatment group assignment and the chronologic order of images. Results. At 24 months, more 25-mg etanercept patients than MTX patients met American College of Rheumatology 20% improvement criteria (72% and 59%, respectively; P = 0.005), and more had no increase in total score and erosion scores on the Sharp scale (P = 0.017 and P = 0.012, respectively). The mean changes in total Sharp score and erosion score in the 25-mg etanercept group (1.3 and 0.66 units, respectively) were significantly lower than those in the MTX group (3.2 and 1.86 units, respectively; P = 0.001). Significantly more patients in the 25-mg etanercept group (55%) than in the MTX group (37%) had at least 0.5 units of improvement in the Health Assessment Questionnaire disability index (P <0.001). Fewer patients in the etanercept group than in the MTX group experienced adverse events or discontinued treatment because of adverse events. Conclusion. Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.

UR - http://www.scopus.com/inward/record.url?scp=0036274944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036274944&partnerID=8YFLogxK

U2 - 10.1002/art.10308

DO - 10.1002/art.10308

M3 - Article

C2 - 12115173

AN - SCOPUS:0036274944

VL - 46

SP - 1443

EP - 1450

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 6

ER -